Breaking News

Clinverse Expands Management Team

July 22, 2014

Williams and Schultz take on VP roles

Shaun Williams has been appointed vice president, Operations at Clinverse, Inc., and Heather Schultz has been named to the newly created role of senior vice president, Product Solutions. 
Mr. Williams will oversee all operational aspects of the company, including implementation services for new clients and ongoing support for existing clients. He has more than 20 years of experience directing a broad range of operational activities in FDA-regulated industries, including medical device, pharmaceutical, and biotechnology. 
Prior to joining the company, he provided consulting services to life sciences companies, specializing in the design and implementation of quality systems for FDA-regulated companies.  
Ms. Schultz will work closely with clients, providing expertise in the development and optimization of the financial lifecycle of clinical trials. Since joining the company in 2011, she served as vice president of Operations, where she developed process standards and a scalable services organization and was responsible for the implementation of ClinPay’s install base. 
Prior to joining Clinverse, she held various roles in global project management, performance optimization, and regulatory affairs at pharma/biotech companies and a large global CRO.  
“We are excited to welcome Shaun to our management team. We look forward to leveraging his experience while continuing to benefit from Heather’s expertise as we remain dedicated to expanding our global client base,” said Denis Connaghan, chief executive officer of Clinverse. “The creation of the SVP, Product Solutions role will allow us to more quickly identify, establish, and support best practices and the integration of new ideas to meet the clinical trial financial management needs of our clients.  Our continued growth is further validation that the market is seeing our automated investigator payment solution as more of a necessity for optimizing the clinical trial process.”

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research